X4 Pharmaceuticals Announces Inducement Grants

Biotech firm issues stock options to new employees under Nasdaq rules

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

X4 Pharmaceuticals, a Boston-based company focused on rare hematology diseases, announced that it has issued inducement awards to new employees in the form of options to purchase 24,000 shares of the company's common stock. The options were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by the company's Compensation Committee.

Why it matters

Inducement grants are a common practice for public companies to attract and retain top talent, especially in competitive industries like biotechnology. These grants provide new employees with a stake in the company's success and align their interests with those of existing shareholders.

The details

The options have a ten-year term and an exercise price of $3.44 per share, which is equal to the closing price of X4's common stock on February 27, 2026. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee's continued employment with X4.

The inducement awards were effective on February 27, 2026.

The players